Pharos iBio financial statements
파로스아이바이오KRX:388870 · KOSDAQ₩6,410-3.61%
2026-10-08 closePharos iBio's published financial data is dated 2026-10-04. 2024 revenue was KRW 0M. 2024 operating profit was −KRW 12.6B.
Reported results
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 4.72
Distress
Grey
Safe
- Altman Z''
- 4.72
- Beneish M-Score
- —
- Sloan accrual
- -6.28%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Quantus Signal · live data · not investment advice · Privacy Policy